These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 23665027

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
    Fleischmann H, Göke R, Bramlage P.
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S91-S97. PubMed ID: 27986406
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, Van Gaal L.
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [Abstract] [Full Text] [Related]

  • 27. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, Horowitz M, Jones KL, Rayner CK.
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [Abstract] [Full Text] [Related]

  • 28. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
    Bolli GB, Owens DR.
    Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
    Dailey GE, Dex TA, Roberts M, Liu M, Meneilly GS.
    J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
    [Abstract] [Full Text] [Related]

  • 30. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
    Liu F, Liu Y, Liu M, Wu G, Zhang M, Zhang X, Cui N, Yin H, Chen L.
    J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
    Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM.
    J Clin Endocrinol Metab; 2019 Feb 01; 104(2):359-368. PubMed ID: 30215735
    [Abstract] [Full Text] [Related]

  • 35. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
    Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH.
    Am J Physiol Renal Physiol; 2019 Feb 01; 316(2):F231-F240. PubMed ID: 30353743
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR, Monnier L, Bolli GB.
    Diabetes Metab; 2013 Dec 01; 39(6):485-96. PubMed ID: 24156868
    [Abstract] [Full Text] [Related]

  • 38. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A, Kapitza C, Hindsberger C, Zdravkovic M.
    Adv Ther; 2011 Mar 01; 28(3):213-26. PubMed ID: 21340616
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.